Pembrolizumab, the approved ICI to treat MMRd/MSI-h patients, targets the PD-1/PD-L1 interaction, and PD-L1 expression on tumour cells has been approved as a biomarker for predicting response to ICIs in some cancer types, such as NSCLC [33]. The gene discussed is CD274; the disease is neoplasm.